
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion Inc. is advancing its clinical pipeline with promising results from its principal drug candidate, icovamenib, which has shown durable, clinically meaningful reductions in HbA1c over 52 weeks in type 2 diabetes subgroups, highlighting significant efficacy in severe insulin-deficient patients. The company has also initiated Phase I trials for its next-generation oral GLP-1 receptor agonist, BMF-650, which demonstrated promising preclinical results, including notable weight reductions and appetite suppression in obese models. Furthermore, while the company reported a net loss of $16.4 million in Q3 2025, this reflects a significant improvement compared to the net loss of $32.8 million in the same quarter the previous year, indicating a trajectory towards better financial health while continuing to invest in its innovative drug development pipeline.
Bears say
Biomea Fusion Inc reported a decrease in research and development (R&D) expenses, totaling $14.4 million in Q3 2025, down from $27.2 million in the same quarter of the previous year, indicating potential challenges in ongoing clinical trials or project advancements. General and administrative (G&A) expenses also saw a decline to $4.2 million from $6.8 million, suggesting cost-cutting measures that may reflect financial strain. Furthermore, the reduction in the price target from $16.00 to $12.00 highlights a less favorable outlook on the company's financial performance and market position.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares